Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors.

Rosenfeld A, Kletzel M, Duerst R, Jacobsohn D, Haut P, Weinstein J, Rademaker A, Schaefer C, Evans L, Fouts M, Goldman S.

J Neurooncol. 2010 Apr;97(2):247-55. doi: 10.1007/s11060-009-0009-z. Epub 2009 Sep 21.

PMID:
19768658
3.

Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.

Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ.

Pediatr Blood Cancer. 2010 Apr;54(4):591-5. doi: 10.1002/pbc.22347.

PMID:
19998470
4.
5.
6.

Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children.

Kellie SJ, Wong CK, Pozza LD, Waters KD, Lockwood L, Mauger DC, White L.

Med Pediatr Oncol. 2002 Sep;39(3):168-74.

PMID:
12210445
7.

High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study.

Namouni F, Doz F, Tanguy ML, Quintana E, Michon J, Pacquement H, Bouffet E, Gentet JC, Plantaz D, Lutz P, Vannier JP, Validire P, Neuenschwander S, Desjardins L, Zucker JM.

Eur J Cancer. 1997 Dec;33(14):2368-75.

PMID:
9616283
8.

High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.

Papadopoulos KP, Garvin JH, Fetell M, Vahdat LT, Garrett TJ, Savage DG, Balmaceda C, Bruce J, Sisti M, Isaacson S, De LaPaz R, Hawks R, Bagiella E, Antman KH, Hesdorffer CS.

Bone Marrow Transplant. 1998 Oct;22(7):661-7.

9.

Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).

Meisenberg BR, Miller WE, McMillan R.

Bone Marrow Transplant. 1996 Dec;18(6):1087-93.

PMID:
8971377
11.

High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.

Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E, Hero B, Selle B, Niemeyer C, Finckenstein FG, Schulz A, Wawer A, Zintl F, Graf N.

Bone Marrow Transplant. 2002 Dec;30(12):893-8.

12.

High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome.

Butturini AM, Jacob M, Aguajo J, Vander-Walde NA, Villablanca J, Jubran R, Erdreich-Epstein A, Marachelian A, Dhall G, Finlay JL.

Cancer. 2009 Jul 1;115(13):2956-63. doi: 10.1002/cncr.24341.

13.

High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma.

Dunkel IJ, Gardner SL, Garvin JH Jr, Goldman S, Shi W, Finlay JL.

Neuro Oncol. 2010 Mar;12(3):297-303. doi: 10.1093/neuonc/nop031. Epub 2010 Jan 11.

14.

A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.

Ozkaynak MF, Sahdev I, Gross TG, Levine JE, Cheerva AC, Richards MK, Rozans MK, Shaw PJ, Kadota RP.

J Pediatr Hematol Oncol. 2008 Mar;30(3):204-9. doi: 10.1097/MPH.0b013e318162bd0c.

PMID:
18376282
15.

Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.

Thorarinsdottir HK, Rood B, Kamani N, Lafond D, Perez-Albuerne E, Loechelt B, Packer RJ, MacDonald TJ.

Pediatr Blood Cancer. 2007 Mar;48(3):278-84.

PMID:
16456857
16.

High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.

Pérez-Martínez A, Lassaletta A, González-Vicent M, Sevilla J, Díaz MA, Madero L.

J Neurooncol. 2005 Jan;71(1):33-8.

PMID:
15719272
17.

Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital.

Campbell AD, Cohn SL, Reynolds M, Seshadri R, Morgan E, Geissler G, Rademaker A, Marymount M, Kalapurakal J, Haut PR, Duerst R, Kletzel M.

J Clin Oncol. 2004 Jul 15;22(14):2885-90.

PMID:
15254057
18.

Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study.

Baek HJ, Park HJ, Sung KW, Lee SH, Han JW, Koh KN, Im HJ, Kang HJ, Park KD.

J Neurooncol. 2013 Sep;114(3):329-38. doi: 10.1007/s11060-013-1188-1. Epub 2013 Jul 4.

PMID:
23824533
19.
20.

Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.

Pession A, Prete A, Locatelli F, Bella S, Melchionda F, Garaventa A, Burnelli R, Paolucci G.

Med Pediatr Oncol. 1999 Nov;33(5):450-4.

PMID:
10531568

Supplemental Content

Support Center